NeuroSense CEO updates shareholders on PARAGON financing, Canada filing, Nasdaq issue
The company said it is still working to fund its Phase 3 ALS trial while preparing a Canadian drug submission and addressing a Nasdaq bid price deficiency.
SEC filing